The venture capital company Asabys Partners, a member of CATALONIA.HEALTH, co-leads a $50 million funding round for the biotechnology company Quibim. It has been through their funds, Sabadell Asabys II, together with Buenavista Equity Partners and with the participation of new investors, such as UI Investissements and GoHub Ventures; and current investors, such as Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures and Leadwind.
The Series A financing round provides a strong boost to the expansion of Quibim’s product portfolio and accelerates its commercial growth on a global scale, consolidating its presence in the United States, after its success in Europe, through strategic collaborations with hospitals and pharmaceutical companies. In line with its strategic plan and taking advantage of its range of FDA-authorized solutions, Quibim will support hospitals and clinical researchers in the efficient processing of large volumes of medical imaging data.
Guillem Masferrer, partner of Asabys Partners, added, “Asabys is thrilled to support Quibim in transforming the imaging diagnostics space. Their ability to combine AI with imaging biomarker discovery addresses critical unmet needs in oncology, neurology, and beyond. We are confident that Quibim’s innovative solutions will have a profound impact on global healthcare.”
Related news:
Comments